WO2019041598A1 – March 7, 2019 – APPLICATION OF GPR55 AND REGULATOR THEREOF IN PREVENTION AND TREATMENT OF IMMUNE SYSTEM DISEASES

Please complete the required fields.




Inventors :

SHI, Yan - D301, Medical Science Building, Tsinghua University, Haidian District, Beijing 100084

Owner :

???? TSINGHUA UNIVERSITY

Application Number :

WOCN17113542

Document Number :

WO2019041598A1

Priority Date :

August 31, 2017

Filing Date :

November 29, 2017

Date of Grant/ Publication :

March 7, 2019

Class :

A61K45 / 00

Abstract

Disclosed is an application of GPR55 and a regulator thereof in prevention and treatment of immune system diseases. The present invention provides an application of GPR55 or a substance capable of promoting the expression of GPR55 or capable of increasing the activity of GPR55 in any one of the following: preparation of products for preventing and/or treating immune disorder-related diseases, and preparation of a product for regulating the function of a peripheral immune system. Experiments show that the inhibitor O-1918 of the cannabinoid receptor GPR55 can inhibit intestinal-derived dendritic cells (expressing CD103, CD11b, and retinal dehydrogenase) from transferring to lymph nodes. The present invention has important significance for preventing and/or treating immune disorder-related diseases such as rheumatism, lupus erythematosus, enteritis and multiple sclerosis, and enhancing the immune function of the body.

Claim(s)

GPR55 or GPR55 of modulators in the following (A)- (D) either in the application: (A) preparation for the prevention and/or treatment of immune-related disorder of the product;
(B) for regulating the peripheral immune system function product;
(C) prevention and/or treatment of immune-related disorder;
(D) adjusting the peripheral immune system function;
The GPR55 regulator GPR55 to be able to facilitate or inhibit the expression of the substance, or can make the GPR55 increase or decrease the activity of the material.;
For preventing and/or treating immune disorders related diseases, is to adopt the GPR55 or GPR55 of the regulator to prevent and/or the treatment of immune-related disorder;
The GPR55 regulator GPR55 to be able to facilitate or inhibit the expression of the substance, or can make the GPR55 increase or decrease the activity of the material.;
A method for regulating the peripheral immune system function method, is to adopt the GPR55 or GPR55 to adjust the outer circumference of the modulators of the immune system function;
The GPR55 regulator GPR55 to be able to facilitate or inhibit the expression of the substance, or can make the GPR55 increase or decrease the activity of the material.;
GPR55 GPR55 or can promote the expression or can make the GPR55 activity to improve material in the following (E)- (H) in the application of any one of: (E) preparation used for driving the source of the dendritic cell to the intestinal tract of the lymph node metastasis from the product;
(F) preparation is used for promoting the development and/or promote the lymph nodes of the lymph nodes of the functioning of the product;
(G) driving intestinal sources of dendritic cell to the lymph nodes;
(H) the promotion of lymph node development and/or promote the function of lymph nodes.;
A drive intestinal sources of dendritic cell to the lymph node metastasis method, is to adopt the GPR55 GPR55 or can promote the expression or can make the GPR55 activity to improve the material to drive the intestinal sources of dendritic cell to the lymph nodes.;
A method for promoting development and/or promote the lymph node lymph node function method, is to adopt the GPR55 GPR55 or can promote the expression or can make the GPR55 activity to improve the material to promote lymph node development and/or promote the function of lymph nodes.;
Can inhibit GPR55 expression or can make the GPR55 activity to reduce material in the following (E ‘) – (H’) either in the application: (E ‘) for inhibition of intestinal sources of dendritic cell to the lymph node metastasis from the product;
(F ‘) for inhibition of lymph node development and/or inhibit the function of the product of the lymph node;
(G ‘) inhibit intestinal sources of dendritic cell to the lymph nodes;
(H ‘) inhibit lymph node development and/or inhibit the function of lymph nodes.;
A method of inhibiting intestinal sources of dendritic cell to the lymph node metastasis method, is to adopt the can inhibit GPR55 expression or can make the GPR55 activity to reduce material to inhibit intestinal sources of dendritic cell to the lymph nodes.;
A method for inhibiting the growth and/or inhibit lymph node lymph node function method, is to adopt the can inhibit GPR55 expression or can make the GPR55 activity to reduce material to inhibit the lymph node development and/or inhibit the function of lymph nodes.;
Application or claim 5 or 8 wherein the method as in Claim 4 or Claim 7, characterized in that said intestinal sources of dendritic cell expression CD103, CD11b and retinal dehydrogenase.;
In any of the application or method according to Claim 7-9, characterized in that said can inhibit GPR55 expression or can make the GPR55 activity to reduce substance for GPR55 inhibitors.;
The use or method according to Claim 11, characterized in that said GPR55 inhibitor is O – 1918.;
Has the following (a)- (d) as shown in the function of at least one kind of the product, its active ingredient is GPR55 GPR55 or can promote the expression or can make the GPR55 activity to improve material;
(A) the prevention and/or the treatment of immune related disorder; (b) adjusting the peripheral immune system function; (c) driving the intestinal sources of dendritic cell to the lymph node metastasis; (d) the promotion of lymph node development and/or promote the function of lymph nodes.;
Has the following (a ‘) – (d’) shown in the function of the at least one of the product, its active ingredient is can inhibit GPR55 expression or can make the GPR55 activity to reduce material;
(A ‘) the prevention and/or the treatment of immune related disorder; (b’) adjusting the peripheral immune system function; (c’) inhibit intestinal sources of dendritic cell to the lymph node metastasis; (d’) inhibit lymph node development and/or inhibit the function of lymph nodes.;
Product as in Claim 13 or Claim 14, characterized in that said intestinal sources of dendritic cell expression CD103, CD11b and retinal dehydrogenase.;
Product as in Claim 14 or Claim 15, characterized in that said can inhibit GPR55 expression or can make the GPR55 activity to reduce substance for GPR55 inhibitors.;
The product according to Claim 16, characterized in that said GPR55 inhibitor is O – 1918.;
In any of the application or method or product according to Claim 1-17, characterized in that the immune related disorder is autoimmune diseases or excessive immune inflammation reaction.;
Application or method or product according to Claim 18, characterized in that said immune disorder associated disease is rheumatism, lupus erythematosus, enteritis, multiple sclerosis or ankylosing spondylitis.;
The application or the method or claim 13 said product according to Claim 4 according to Claim 5, characterized in that said driving intestinal sources of dendritic cell to the lymph node metastasis is driving said intestinal sources of dendritic cell to the mesenteric lymph nodes and/or non-intestinal exoplanets week of lymph node metastasis.;
claim 21: The application or the method or claim 14 said product according to Claim 7 according to Claim 8, characterized in that inhibit intestinal sources of dendritic cell to the lymph nodes in order to inhibit said intestinal sources of dendritic cell to the mesenteric lymph nodes and/or non-intestinal exoplanets week of lymph node metastasis.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login